Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00582010
Other study ID # F070112003
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received December 20, 2007
Last updated November 5, 2014
Start date April 2008
Est. completion date October 2012

Study information

Verified date October 2014
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This blinded, placebo-controlled study will administer inhaled nitric oxide to patients undergoing liver transplantation. The purpose of the study is to test if inhaled nitric oxide prevents liver injury associated with the restoration of blood flow. The premise of the current study is provided by previous studies which document a protective effect of inhaled nitric oxide in this clinical setting.


Description:

Specifically, presenting ischemia-reperfusion injury to transplanted livers remains a therapeutic goal in improving liver function and potentially expanding the number of transplantable livers. This study aims to assess the efficacy of inhaled nitric oxide to limit ischemia-reperfusion injury in transplanted livers and by doing so improve liver function post transplantation and decrease patient hospital length of stays.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date October 2012
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients > 19 yr of age scheduled to undergo liver transplantation.

Exclusion Criteria:

- Patients < 19 yr of age

- Patients undergoing re-transplantation or dual organ transplantation

- Patients with underlying pulmonary complications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
inhaled nitric oxide
inhaled 80ppm for duration of surgery.
nitrogen gas
inhaled

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States University of Washington Seattle Washington

Sponsors (3)

Lead Sponsor Collaborator
University of Alabama at Birmingham Mallinckrodt, University of Washington

Country where clinical trial is conducted

United States, 

References & Publications (1)

Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, Liu Y, Jhala N, Crowe DR, Smith AB, Cross RC, Frenette L, Kelley EE, Wilhite DW, Hall CR, Page GP, Fallon MB, Bynon JS, Eckhoff DE, Patel RP. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest. 2007 Sep;117(9):2583-91. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in AST Levels) The faster the percent decrease of AST reflect the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. The rate was calculated by measuring AST levels at baseline and at 96 hours post baseline. (AST levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of AST relative to baseline). baseline and 96 hours after baseline
Primary Changed Rate of Liver Function Recovery Post-transplantation (Percent Change in ALT Levels) The faster the percent decrease ALT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. . (ALT levels were lower at 96 hours relative to baseline- positive values in data table indicate percent decrease of ALT relative to baseline). baseline and 96 hours after baseline
Primary Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Alkaline Phosphatase Levels) The faster the percent increase of alkaline phosphatase reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an increase; a negative percentage reflects a decrease. baseline and 96 hours after baseline
Primary Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Prothrombin Times (PT)) The faster the percent increase of PT reflect, the greater the treatment improved liver function post transplant. A positive percent reflects an decrease; a negative percentage reflects a increase. baseline and 96 hours after baseline
Primary Change in Rate of Liver Function Recovery Post-transplantation (Percent Change in Bilirubin Levels) A positive percent reflects an decrease; a negative percentage reflects a increase. baseline and 96 hours after baseline
Primary Change in Rate of Liver Function Recovery Post-transplantation (Decrease in Hepatobiliary Complications) Number of complications due to hepatobiliary events. baseline to 9 months after transplantation
Primary Number of Complications Related to Liver Function Recovery Post-transplantation (Total Complications) at 9 Months Post Surgery Number of any complication reported by subjects at 9 months after surgery baseline to 9 months post surgery
Secondary Effect of iNO on Hosptial Length of Stay number of days subject in hospital after surgery until discharge from surgery through discharge from hospital
Secondary Effect of iNO on SICU Stay Number of minutes after surgery subject remained in SICU baseline to discharge for SICU
See also
  Status Clinical Trial Phase
Completed NCT02251041 - Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL) Phase 2
Completed NCT01944605 - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest N/A
Completed NCT00778323 - Clinical Trial of Remote Preconditioning in Patients Undergoing Cervical Decompression Surgery Phase 1/Phase 2
Completed NCT00994981 - Magnesium Administration in Liver Transplantation and Reperfusion Injury Phase 4
Completed NCT00529607 - Diagnostics for the Reperfusion Injury Following MI N/A
Completed NCT02286544 - Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers Phase 1
Completed NCT02731651 - Effect of Pneumoperitoneum on Human Ovary N/A
Active, not recruiting NCT00189007 - Antenatal Allopurinol During Fetal Hypoxia Phase 3
Completed NCT01167569 - Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients Phase 4
Completed NCT00246740 - Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Phase 2
Enrolling by invitation NCT05725694 - Acute Ischaemic STROKE: From LAboratory to the Patient's BED
Completed NCT00402506 - A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Phase 3
Completed NCT03176823 - Remote Ischemic Conditioning as a Treatment for Traumatic Brain Injury N/A
Completed NCT02512640 - Comparison of Oxidative Stress Changes in Different Ventilation Strategies During Gynecologic Laparoscopic Surgery N/A
Recruiting NCT05574296 - Hydrogen's Feasibility and Safety as a Therapy in ECPR Phase 1
Active, not recruiting NCT02127996 - GLP-1 Loading During Elective Percutaneous Coronary Intervention Phase 2
Suspended NCT02850471 - Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery Phase 1/Phase 2
Terminated NCT02394405 - Myocardial and Renal Dysfunction by Oxidative Stress Caused by Cardiac Surgery
Completed NCT00516711 - Role of Volatile Anesthetics for Hepatic Protection N/A
Terminated NCT04316468 - Cardiac Strain Using Speckle Tracking Echocardiography During Orthotopic Liver Transplantation